Long-term efficacy and safety of oral encainide in the treatment of chronic ventricular ectopic activity: relationship to plasma concentrations--a French multicenter trial.
To establish long-term efficacy and safety of encainide, 48 patients with chronic premature ventricular contractions (PVCs) underwent 6 months of therapy with encainide. Twenty-four-hour ambulatory ECGs were obtained at baseline for each daily dosage of 75 mg, 150 mg, and 225 mg of encainide during the in-hospital titration period and at the end of the first and sixth months during the follow-up period. There was a significant reduction in the median hourly total PVC rates from 480.6 at baseline to 2.0 at the end of the titration period with the highest dosage and to 22.1 at the last visit of the chronic dosing period. Nearly total suppression of PVCs was observed in 56% of patients at the end of the titration period and in 30% at the end of the 6-month follow-up period. The most common side effects were vertigo, vision disturbance, and headache. PR, QRS, and QTc intervals showed consistent significant increases from baseline during the various encainide trial periods. Encainide may have worsened ventricular arrhythmia in four patients who received more than 200 mg of encainide daily. Plasma concentrations of encainide and encainide metabolites showed wide interpatient variation, and no relationship was found between antiarrhythmic efficacy and plasma levels of encainide, O-demethyl-encainide, or 3-methoxy-O-demethyl-encainide.
P
P
Dumoulin
P
P
Jaillon
A
A
Kher
J M
JM
Poirier
G
G
Cheymol
J
J
Valty
D
D
Flammang
P
P
Coumel
J L
JL
Medvedowsky
C
C
Barnay
D000293:Adolescent; D000328:Adult; D000368:Aged; D000813:Anilides / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004562:Electrocardiography; D016700:Encainide / Q000031:analogs & derivatives; D005260:Female; D005602:France; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008875:Middle Aged
D000813:Anilides; D000889:Anti-Arrhythmia Agents; C033635:O-demethylencainide; C033636:3-methoxy-O-demethylencainide; D016700:Encainide